Phase II Trial Of Induction Gemcitabine/CPT-11 Followed By Twice-Weekly Infusion Gemcitabine And Concurrent External Beam Radiation For The Treatment Of Locally Advanced Pancreatic Cancer
- Determine the time to progression, local control, and survival of patients with locally
advanced, unresectable pancreatic cancer treated with induction gemcitabine and
irinotecan followed by gemcitabine and concurrent radiotherapy.
OUTLINE: Patients receive induction gemcitabine IV over 30 minutes and irinotecan IV over 90
minutes on days 1 and 8. Treatment repeats every 3 weeks for 2 courses in the absence of
disease progression or unacceptable toxicity.
Within 2 weeks of completing induction chemotherapy, patients receive gemcitabine IV over
30-60 minutes on days 1, 4, 8, 11, 15, 18, 22, 25, 29, and 32. Patients undergo concurrent
radiotherapy 5 days a week for 5.5 weeks.
Patients are followed every 8 weeks for 6 months and then every 3 months for 1.5 years.
PROJECTED ACCRUAL: Approximately 60-120 patients will be accrued for this study within 1-2
Primary Purpose: Treatment
Arthur William Blackstock, MD
Comprehensive Cancer Center of Wake Forest University
United States: Federal Government
|Lineberger Comprehensive Cancer Center, UNC||Chapel Hill, North Carolina 27599-7295|
|East Carolina University School of Medicine||Greenville, North Carolina 27858-4354|
|Comprehensive Cancer Center at Wake Forest University||Winston-Salem, North Carolina 27157-1082|
|Greenville Hospital System||Greenville, South Carolina 29605|
|Hollings Cancer Center at Medical University of South Carolina||Charleston, South Carolina 29425|
|Southeastern Medical Oncology Center||Goldsboro, North Carolina 27534|
|Spartanburg Regional Healthcare System||Spartanburg, South Carolina 29303|